| Description | BB-Cl-Amidine hydrochloride is an inhibitor of peptidylarginine deminase (PAD) [1]. |
| In vivo | Treatment with BB-Cl-amidine subtly reduces splenomegaly in MRL/lpr mice, while there is a trend towards increased circulating levels of anti-NET antibodies with PAD inhibitor treatment. However, neither PAD inhibitor affected body weight or total IgG levels. In fact, treatment with both Cl-amidine and BB-Cl-amidine significantly improves endothelium-dependent vasorelaxation. The BB-Cl-amidine group also shows a strong trend towards downregulation of IRGs. Treatment with either Cl-amidine or BB-Cl-amidine significantly improves muzzle alopecia, in many cases preventing it entirely [1]. Animal Model: MRL/lpr mice [1]. Dosage: 1 mg/kg. Administration: Subcutaneous injection daily from 8 to 14 weeks of age. Result: Significantly improved endothelium-dependent vasorelaxation and showed a strong trend towards downregulation of IRGs. |
| Synonyms | BB-Cl-Amidine hydrochloride (1802637-39-3 free base) |
| molecular weight | 496.43 |
| Molecular formula | C26H27Cl2N5O |
| CAS | 2436747-41-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 100 mg/mL (201.44 mM) |
| References | 1. Knight JS, et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis. 2015 Dec;74(12):2199-206. |